Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.49 |
| ▸ | AXL | P30530 | 5/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9609153 | 0.89 | MET (0.49) | PDGFRBPDGFRAFGFR2AXLMET | |
| SCHEMBL371669 | 0.89 | MET (0.48) | PDGFRBPDGFRAAXLMET | |
| SCHEMBL3894223 | 0.87 | SRC (0.45) | PDGFRBPDGFRAFGFR2AXLSRC | |
| SCHEMBL14999154 | 0.84 | SRC (0.39) | PDGFRBPDGFRAAXLSRCTGFBR1 | |
| SCHEMBL632944 | 0.84 | LMNA (0.52) | PDGFRBPDGFRAAXL | |
| SCHEMBL3551410 | 0.84 | HTR1A (0.46) | MET | |
| SCHEMBL2747292 | 0.84 | PDGFRB (0.59) | PDGFRBPDGFRAFGFR2AXLMET | |
| SCHEMBL23528183 | 0.82 | PDGFRA (0.56) | PDGFRBPDGFRAFGFR2METSRC | |
| SCHEMBL1889615 | 0.82 | PDGFRA (0.64) | PDGFRBPDGFRAFGFR2AXLMET | |
| SCHEMBL22521173 | 0.81 | AXL (0.61) | PDGFRAFGFR2AXLMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11498902-B2 | Process for the preparation of Cabozantinib and its pharmaceutically acceptable salts thereof | NATCO PHARMA LIMITED (IN) | 2022-11-15 | — | — | US | disclosed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20180237378-A1 | Asymmetric Bisamidation of Malonic Ester Derivatives | SANDOZ AG (CH) | 2018-08-23 | — | — | US | disclosed |
| EP-3337786-A1 | ASYMMETRIC BISAMIDATION OF MALONIC ESTER DERIVATIVES | Sandoz AG (CH) | 2018-06-27 | — | — | EP | disclosed |
| WO-2006108059-A1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| EP-1673085-A2 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030140-A2 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5656643-A | QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| US-5409930-A | Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | PDGFRB 30/4885PDGFRA 63/4885FGFR2 590/4885 |
| US-20180237378-A1 | Asymmetric Bisamidation of Malonic Ester Derivatives | MAL2, ALK, ME1 | PDGFRB 486/4885PDGFRA 532/4885FGFR2 518/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | PDGFRB 30/4885PDGFRA 63/4885FGFR2 590/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | PDGFRB 30/4885PDGFRA 63/4885FGFR2 590/4885 |
| US-11498902-B2 | Process for the preparation of Cabozantinib and its pharmaceutically acceptable salts thereof | FIP1L1, ABL1, FGFR1 | PDGFRB 13/4885PDGFRA 4/4885FGFR2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.